Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered

- Men or women

- Body mass index > 19 and < 28.5 Kg/m2

- Is able to understand the Informed Consent Form (ICF)

- Women in their menstrual period;

- Diseases that interfere with the absorption, distribution and excretion of drugs, such as history or presence of hepatic or renal diseases;

- Presence of active genital lesions or sexually transmitted disease (STD) (such as herpes, gonorrhea, candidiasis, Human Papillomavirus, and others) that impair analysis of local adverse effects on the genitalia;

- History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patients with heart disease (including a history of angina and/or heart failure) and nephropathies;

- Findings on ECG and/or laboratory tests that, in the investigator's judgment, are considered the research volunteer's participation or may interfere with the analysis of the study of the study;

- Blood pressure (BP) outside the limits considered safe: systolic BP (SBP) 90 - 140 mmHg and diastolic BP diastolic BP (DBP) 60 - 90 mmHg, except for situations such as "white coat syndrome";

- Any disease or condition or physical finding that the investigator considers significant and that increases the risk

- Any disease or condition or physical finding that the investigator considers significant and that increases the risk of participation of the research volunteer or may interfere with the results.